Evaluation of the pharmacodynamics, pharmacokinetics and safety of repeated escalating oral doses of S 38844 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunction A phase II, randomised, double-blind, parallel-group, placebo controlled, international multicentre study.
Phase of Trial: Phase II
Latest Information Update: 25 Aug 2015
At a glance
- Drugs S 38844 (Primary)
- Indications Chronic heart failure; Left ventricular dysfunction
- Focus Pharmacodynamics
- Sponsors IRIS
- 11 Jul 2015 Status changed from recruiting to completed, according to European Clinical Trials Database record.
- 16 Jul 2013 New trial record